Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Pre-Analytical Parameters Affecting Vascular Endothelial Growth Factor Measurement in Plasma: Identifying Confounders

Pre-Analytical Parameters Affecting Vascular Endothelial Growth Factor Measurement in Plasma: Identifying Confounders

  • Johanna M. Walz, 
  • Daniel Boehringer, 
  • Heidrun L. Deissler, 
  • Lothar Faerber, 
  • Jens C. Goepfert, 
  • Peter Heiduschka, 
  • Susannah M. Kleeberger, 
  • Alexa Klettner, 
  • Tim U. Krohne, 
  • Nicole Schneiderhan-Marra



Vascular endothelial growth factor-A (VEGF-A) is intensively investigated in various medical fields. However, comparing VEGF-A measurements is difficult because sample acquisition and pre-analytic procedures differ between studies. We therefore investigated which variables act as confounders of VEGF-A measurements.


Following a standardized protocol, blood was taken at three clinical sites from six healthy participants (one male and one female participant at each center) twice one week apart. The following pre-analytical parameters were varied in order to analyze their impact on VEGF-A measurements: analyzing center, anticoagulant (EDTA vs. PECT / CTAD), cannula (butterfly vs. neonatal), type of centrifuge (swing-out vs. fixed-angle), time before and after centrifugation, filling level (completely filled vs. half-filled tubes) and analyzing method (ELISA vs. multiplex bead array). Additionally, intrapersonal variations over time and sex differences were explored. Statistical analysis was performed using a linear regression model.


The following parameters were identified as statistically significant independent confounders of VEGF-A measurements: analyzing center, anticoagulant, centrifuge, analyzing method and sex of the proband. The following parameters were no significant confounders in our data set: intrapersonal variation over one week, cannula, time before and after centrifugation and filling level of collection tubes.


VEGF-A measurement results can be affected significantly by the identified pre-analytical parameters. We recommend the use of CTAD anticoagulant, a standardized type of centrifuge and one central laboratory using the same analyzing method for all samples.


Vascular endothelial growth factor-A (VEGF-A) is a key player in physiologic as well as pathologic angiogenesis [1, 2]. A variety of diseases ranging from tumor growth [3, 4], through asthma [5] to exudative age-related macular degeneration [6] are associated with a deregulation of this angiogenic factor. As a consequence, anti-VEGF therapeutics have been developed to target pathologic angiogenesis in various contexts: Anti-VEGF drugs alone or in combination improved survival rates or progression-free survival rate in certain cancer types [3, 711]. Anti-VEGF drugs also have been investigated in ophthalmology in randomized clinical trials [1215] and have been found to improve treatment outcomes [16, 17].

Along with the increasing clinical role of anti-VEGF compounds, VEGF-A itself has been investigated intensively as a potential diagnostic biomarker or as a predictive marker for treatment response [1820]. In addition, antagonizing VEGF-A has been found in some studies to be associated with a significantly increased risk of myocardial infarction, hypertension and stroke [2123]. Even small amounts of intravitreally injected VEGF-binding agents were found to alter systemic VEGF-A levels [2426]. As a consequence, determination of systemic VEGF-A levels is part of the systemic safety analysis in various studies investigating VEGF-binding proteins [25, 2729]. However, due to the use of different protocols in quantifying systemic VEGF-A levels, comparison of the results remains difficult.

The aim of this study was therefore to investigate the independent impact of various pre-analytical parameters on the assessment of VEGF-A levels in blood samples from healthy volunteers. Identifying these sources of bias and noise will improve the reliability of future VEGF-A readings and will help to clarify the role of angiogenic factors in disease and response to therapy.


Sample acquisition and distribution

Blood samples from six healthy volunteers (three male, three female, aged between 20 and 40 years) were taken for the initial data set at three centers, two at each center (one male, one female). For additional experiments, blood samples were taken from eight participants (four female and four male). All procedures for obtaining blood samples were standardized following a detailed protocol: blood was first taken from the male participant, then from the female participant in a lying position. Blood sampling had to be scheduled between 7:30 and 10 a.m. Participants had to come to the site in a fasting status with last meal eaten before midnight the previous day and with no extraordinary stress exposure (e.g. excessive sports) the day before. Blood was taken first with a neonatal cannula and then with a butterfly needle. In order to avoid long stasis, the tourniquet was released directly after venous puncture and before blood was collected. The first drops of blood were discarded. After centrifugation of blood samples and before analysis, all aliquots were stored at -20°C and shipped on dry ice if applicable.

Sample acquisition was repeated one week later in order to investigate intrapersonal variations in VEGF-A levels over time. Each center deliberately altered predefined pre-analytical parameters to investigate this parameter's impact on VEGF-A measurements. One aliquot from each sample was measured at the site of blood sampling, one aliquot from the same sample was sent to a second independent measuring center and a third aliquot was sent to a central laboratory. By this approach, each sample was measured independently at three different centers (acquisition center, measuring center and central laboratory) in order to investigate whether the parameter "center" was an independent confounder of VEGF-A measurements. The process of sample acquisition and distribution is illustrated in Fig 1.

Fig 1. Overview of sample acquisition procedures and the distribution of samples from blood acquisition centers to measuring centers and central laboratory.

Parameters investigated

All parameters investigated as potential confounders of systemic VEGF-A levels are listed in Table 1.

Analyzing kits for measured parameters

The measurement of VEGF-A was done at all centers with the same batch of ELISA kit (R&D Cat No. DVE00). At the central laboratory VEGF-A was additionally measured with a Luminex assay (R&D Systems, Human VEGF High Sensitivity Kit Cat No. LHSCM293). Platelet-factor-4 (PF-4) was measured using an ELISA kit from R&D Systems (Cat. No. DPF40). IGF-1 was measured using an ELISA kit from R&D Systems (Cat. No. DG100).

Missing values and values under the limit of detection

Values that were missing from one center because this center did not have this sample were omitted. Paired analysis was not performed in those cases and samples were excluded from the linear regression model. In total, 6 out of 404 aliquots were excluded due to missing values. Values under the limit of detection (provided by the manufacturer of each kit as minimal detectable dose (MDD)) were uniformly replaced by half the MDD value. For the VEGF-A ELISA assay, MDD was given as 9 pg/ml by the manufacturer, for the VEGF-A Luminex assay MDD was 1,74 pg/ml, for the IGF-1 ELISA MDD was 22,4 ng/ml and for the PF-4 ELISA MDD was 4,63 pg/ml.

Statistical Analysis

Multiple regression analysis was performed using a linear regression model to assess the independent parameters affecting VEGF-A plasma measurements. Computations were performed using R. Significance of statistical difference is indicated by asterisks *p<0.05, **p<0.01, ***p<0.001; ns: not statistically significant. In addition to the multiple regression analysis we performed descriptive paired analyses using Spearman’s correlation to measure coefficients of determination (R2) where appropriate. Data are presented as Tukey box plots and bar charts with standard deviation.


This study was approved by the Ethics Committee at the University of Freiburg, Germany and all participating centers. Participants provided their written informed consent to participate in this study.


All VEGF-A levels reported in this section were measured by ELISA unless otherwise stated. The central laboratory samples were measured in single aliquots. At all other centers, samples were measured as technical duplicates and mean values were used for further statistical analysis.

Multiple regression analysis

Results from the multiple regression analysis are shown in Table 2. The following parameters were identified as statistically significant independent confounders of VEGF-A levels: analyzing center, anticoagulant, type of centrifuge, measuring method and sex of the healthy volunteer. The linear regression model estimates VEGF-A levels measured at the various centers to be between 32 pg/ml lower (center D) and 35 pg/ml higher (center E) compared to the central laboratory that was set as reference. Multiplex bead array measurements are estimated to be on average 38 pg/ml lower compared to ELISA measurements. Female participants had on average 24 pg/ml higher VEGF-A levels compared to male participants in our data set. Both, PECT anticoagulant (-34 pg/ml) as well as in particular CTAD anticoagulant (-73 pg/ml) resulted in significantly lower VEGF-A measurements compared to EDTA. Using a centrifuge with a swing-out rotor yielded on average of 23 pg/ml lower VEGF-A values compared to a fixed-angle centrifuge.

The following parameters were NOT identified as independent confounders of VEGF-A levels in our data set: intrapersonal variation over one week (-3 pg/ml at second vs. first time point), cannula (+5 pg/ml for neonatal vs. butterfly), time before centrifugation (-8 pg/ml if waiting up to 2 hours), time after centrifugation (+8 pg/ml if waiting up to 6 hours) and filling level of collection tube (+7 pg/ml for half-filled vs. completely filled tubes).

Paired analysis

In addition to the linear regression model, we analyzed the following parameters in a descriptive analysis in order to better visualize their impact on mean values and range of measured values.

Monovariante center comparison.

The box-plot analysis and paired plot comparisons shown in Fig 2.1(a–c) clearly illustrate the variability of results obtained at different centers by measuring aliquots that were taken from the same participants, processed in the same manner and analyzed using the same batch of an ELISA kit. In some cases, a good correlation between the centers and the central laboratory is observed, e.g. center E and F (R2 = 0.98 and 0.95, respectively). In contrast, high deviations were found for other centers, for example when comparing center A (R2 = 0.79) and center C (R2 = 0.5) to the central laboratory. Fig 2.1a depicts results for all samples that were taken at center A with aliquots being sent to center B and the central laboratory for ELISA measurements. It is obvious that measured VEGF-A values from identical aliquots differed depending on the center at which the measurements were performed. A similar effect was observed for samples that were collected at center C with identical aliquots measured at centers C, D and the central laboratory (Fig 2.1b). Fig 2.1c shows good correlation between samples obtained at center E and measured at center E, F and the central laboratory.

Fig 2.

2.1 (a-c) Paired plots (light orange) and box plots (blue) of VEGF-A levels measured at blood taking centers, measuring centers and at the central laboratory (CL). Connecting lines illustrate the measured VEGF-A levels from identical aliquots of samples measured at the acquisition center, the measuring center and the central laboratory; 2.2 Impact of the anticoagulant (EDTA, PECT, CTAD) on measurement of VEGF-A, PF-4 and IGF-1 from plasma. VEGF-A levels measured from PECT (a) and CTAD (b) plasma are much lower than from EDTA plasma. Similar to VEGF-A, PF-4 values are higher in EDTA plasma than in PECT (c) or CTAD (d) plasma, indicating increased thrombolysis in EDTA samples compared to PECT or CTAD. IGF-1 levels are not affected by the choice of anticoagulant (e, f) indicating that the choice of coagulant is not a general confounder for all biomarkers. (g) VEGF-A levels obtained after spiking VEGF-A into PBS containing EDTA, PECT or CTAD yielded comparable results thus confirming that CTAD or PECT do not interfere with the VEGF ELISA assay. It was noted, however, that VEGF stored at -80°C for over one year yields lower recovery rates in all samples, irrespective of the anticagulant used; 2.3 Impact of the kind of centrifuge used for separating plasma from the cell pellet (equivalent settings were applied). VEGF-A (a) and PF-4 (b) levels were higher in some samples from the fixed angle rotor compared to the swing-out rotor. IGF-1 levels (c) were not affected by the type of centrifuge; 2.4 Comparison of measurements obtained with two methods: ELISA vs. multiplex bead array (Luminex). (a) box-plot analysis showing that absolute values differ between the two measurement methods; (b, c) scatter plot and Bland-Altmann plot, however, demonstrate a good correlation of relative measurement results from the two methods; (d, e) VEGF-A protein standards from both the ELISA kit and the Luminex kit were measured in both assays. In either assay, the VEGF-A standard provided with the Luminex kit resulted in higher signals for identical protein concentrations compared to the VEGF-A standard provided with the ELISA kit. This translates in lower measurements of patient sample VEGF-A levels when these are normalized to the Luminex VEGF-A standard as opposed to the ELISA standard (irrespective of the assay used).

Anticoagulants: EDTA, PECT and CTAD.

VEGF-A in the systemic circulation is stored in thrombocytes to a great extent [33]. Thrombolysis therefore represents a potent confounder for measurement of free VEGF-A plasma levels and must consequently be avoided by using appropriate anticoagulants. EDTA is the most widely used anticoagulant in clinical routine, but both PECT and CTAD anticoagulants have been suggested as alternatives with potential superior effects in preventing thrombocyte activation [3032]. For both PECT and CTAD, lower amounts of free VEGF-A were measured compared to EDTA plasma in samples from the same participants taken at the same time point using the same method (Fig 2.2a and 2.2b). This may in part be explained by higher thrombocyte activation in EDTA samples compared to CTAD or PECT samples as reflected by higher readings for PF-4, a factor usually stored in thrombocytes and released upon thrombocyte activation (Fig 2.2c and 2.2d). When put into relation to values of VEGF-A levels obtained with EDTA, VEGF-A levels obtained with CTAD were lower than those obtained with PECT, indicating that unwanted release of VEGF-A by thrombocytes may even be lower when CTAD is used compared to PECT. There is no general effect of the anticoagulant on protein biomarkers because IGF-1 determination was not affected by the choice of anticoagulant (Fig 2.2e and 2.2f).

In order to evaluate whether the lower VEGF levels in the CTAD and PECT samples could be due to the two anticoagulants interfering with the ELISA assay, we added known concentrations of recombinant VEGF-A to PBS containing either EDTA, PECT or CTAD (Fig 2.2g). There was no difference in the recovery rate of spiked-in VEGF-A, confirming that CTAD and PECT do not interfere with the VEGF ELISA assay. However, it was notable that older aliquots of recombinant VEGF-A (stored over one year at -80°C) yields significantly lower recovery rates in all samples tested. Furthermore, it was confirmed that both assays measure only free VEGF-A (S1 Fig).

Type of centrifuge: fixed angle vs. swing-out rotor.

The type of centrifuge could be an important pre-analytic parameter with impact on VEGF-A readings since pellet formation and pellet density in fixed angle vs. swing-out rotor centrifuges may lead to different degrees of contamination of plasma samples with pellet components such as cell debris containing VEGF-A from intracellular sources. In direct comparison, slightly higher VEGF-A levels were detected when samples were centrifuged with a fixed angle vs. a swing-out rotor centrifuge (Fig 2.3a). This difference was identified as an independent confounder of VEGF-A readings in the linear regression analysis (see Table 2). Interestingly, high PF-4 levels, indicative of thrombocyte activation, were mainly observed in samples centrifuged with a fixed-angle rotor (Fig 2.3b). IGF-1 levels were measured as an additional independent biomarker but were not affected by different centrifugation conditions (Fig 2.3c).

Measuring method.

The most widely used methods to measure VEGF-A are ELISA and multiplex bead arrays [3438]. Therefore, the amount of VEGF-A was determined in all samples using these two methods. As shown in Fig 2.4, absolute readings from the two assays cannot be compared. In our hands, multiplex bead array measurements resulted in lower values compared to ELISA measurements: Median VEGF-A level measured by ELISA was 36 pg/ml (IQR: 19–63 pg/ml), whereas median VEGF-A level measured by multiplex bead array was 10 pg/ml (IQR: 7–18 pg/ml). This influence of analytical method was identified as an independent confounder in the linear regression analysis (see Table 2). The scatter plot (Fig 2.4b) and the Bland-Altmann plot (Fig 2.4c) indicate a good correlation between the two methods, although absolute values were not identical.

In order to further evaluate the differences between the two measuring methods, we measured standard curves produced with the VEGF calibrator protein supplied with both kits in both assays. The results showed that the VEGF-A provided with the Luminex kit gives higher signals for identical protein concentration (as specified by the manufacturer) irrespective of the assay used. This means that measured sample concentrations, which are back-calculated using a standard curve produced with the calibrator protein from the Luminex kit, result in lower concentrations of target VEGF independent of the assay used (Fig 2.4d and 2.4e).

Extreme values.

The ability of a method to correctly retrieve known values at the upper and lower assay range is an important parameter for ensuring data consistency for samples containing very high or low analyte concentrations. Therefore, samples with known VEGF-A levels were either diluted or spiked with fixed amounts of VEGF-A (spike-in recovery), and it was investigated if the expected levels of VEGF-A could be determined correctly by ELISA or multiplex bead array (Fig 3).

Fig 3.

(a) Comparison of the mathematically expected and measured VEGF-A levels after a 1:5 and 1:10 sample dilution. Both ELISA and multiplex bead array measurements measure slightly higher values than mathematically expected after sample dilution; (b) Addition of up to 1.333 pg/ml of recombinant VEGF-A to a plasma sample yields recovery rates of about 80% in all anticoagulants. Exp. = expected value; Meas. = measured value.

For diluted samples measured with ELISA, we found values close to the expected analyte concentrations, if a previously measured sample was re-measured in a 1:10 dilution. Samples re-measured by ELISA after a 1:5 dilution tended to result in slightly higher values than mathematically expected (Fig 3a). The multiplex bead array method also measured slightly higher values than expected both after a 1:5 as well as after a 1:10 dilution (Fig 3a).

When samples with spiked-in VEGF-A were measured by ELISA, observed recovery rates were approximately 80% (Fig 3b). These experiments were performed only at our central laboratory to test basic assay performance and were therefore not included in the linear regression model.

Time before and after centrifugation.

We investigated whether storing blood samples before or after centrifugation would affect VEGF-A readings. When EDTA plasma samples were stored at room temperature for up to two hours before centrifugation, VEGF-A levels were only increased in a few samples (Fig 4a). PF-4 readings also tended to be slightly higher in samples with longer incubation times and correlated with higher VEGF-A readings (Fig 4b). This was, however, not found to be a significant independent confounder of VEGF-A readings in the linear regression model (see Table 2). In an additional experiment, we evaluated whether even longer waiting times (up to 24 hours before centrifugation) would affect VEGF-A readings. While long-term storage before centrifugation had a significant impact on VEGF-A readings from EDTA samples, there was no change in PECT or CTAD samples (Fig 4c).

Fig 4. Impact of time before (a,b,c) and after (d-g) centrifugation on measured VEGF-A and PF-4 levels.

In some EDTA samples, VEGF-A (a,c,d) and PF-4 levels (b,f) increased with longer incubation times. This was particularly significant when EDTA samples were stored for longer periods of time before centrifugation (c). In PECT samples (c,e,g), VEGF and PF-4 values were not affected by longer sample storage times.

A subset of EDTA- and PECT plasma samples was stored at room temperature or at 4°C, respectively, for up to 6 hours after centrifugation before the plasma was separated from the cell pellet. In some of the EDTA plasma samples, higher VEGF-A levels were measured (Fig 4d). This was, however, not significant in the linear regression model (see Table 2). Importantly, none of the samples collected in PECT anticoagulant showed a detectable change in measured VEGF-A levels over time (Fig 4e). In support of the notion that PECT anticoagulant very potently inhibits thrombocyte activation, we found considerably higher PF-4 values in EDTA samples compared to PECT samples (Fig 4f and 4g; note the different y-axis in the two PF-4 graphs).

Butterfly vs. neonatal cannula.

Variations in blood sample acquisition can significantly affect measurement results. For example, this is well established for potassium sampling when release of intracellular potassium leads to erroneous high plasma readings after partial cell lysis during sample acquisition [39]. Likewise, thrombolysis occurring during sample acquisition might result in incorrect high VEGF-A levels. Since VEGF-A measurements have become increasingly important also in neonatal patients with the advent of anti-VEGF treatment in infants suffering from retinopathy of prematurity (ROP), VEGF-A levels were determined in samples obtained with neonatal cannulas or with standard butterfly needles (all taken from the same adult participants). The scatter plot in Fig 5a indicates a minor trend for higher VEGF-A readings in some samples that were obtained with neonatal cannulas. Many values, however, are located near the bisecting line indicating comparable measurement results. The kind of cannula was not a statistically significant independent confounder in the linear regression analysis (see Table 2).

Fig 5. (a) Scatter plot for the influence of cannula (neonatal vs. butterfly) on measured VEGF-A plasma levels; (b) Scatter plot for intrapersonal fluctuations in plasma VEGF-A levels over one week; (c) Scatter plot for the impact of filling level of blood collection tubes on the resulting VEGF-A levels.

Location of values near the bisecting line indicates comparable measurement results.

Intrapersonal fluctuations over one week.

In order to investigate whether VEGF-A levels vary in healthy participants over time, systemic VEGF-A levels were re-measured in new samples obtained from the same individuals after one week. Slight variations were observed, but these were not identified as independent confounders in the linear regression model (Fig 5b and Table 2).

Filling level of the collection tubes.

In clinical routine, sample tubes are not always filled completely. This leads to altered ratios of sample volume to anticoagulant. Fig 5c shows the scatter plot for completely filled vs. half-filled tubes. There was no difference found (most values are located near the bisecting line) and accordingly, filling level was not identified as an independent confounder in the linear regression analysis (see Table 2).


Systemic VEGF-A levels are measured as biomarkers in different medical fields, such as oncology [30, 40], pneumology [41] and ophthalmology [28, 3537]. Absolute values for VEGF-A levels vary noticeably between studies (e.g. plasma VEGF-A levels of healthy probands were reported to be between 81 pg/ml [42] and 180 pg/ml [35]) and therefore, cross-study comparisons are difficult. This is due to the fact that the methodology for VEGF-A measurements from human blood differs and that various confounders, e.g. source (plasma or serum [30, 31, 36, 43]), blood sampling techniques and anticoagulants (heparin plasma [44], CTAD plasma [28], EDTA plasma [45] or others [31]), can considerably affect measurable VEGF-A levels. In this study, we identified a number of parameters that can all independently lead to a bias of measured VEGF-A values from human blood samples. These parameters are: type of anticoagulant, assay method, center performing the measurement, type of centrifuge, sex of the participant. These parameters are extremely important to consider when systemic VEGF-A is measured for example as part of a safety evaluation after anti-VEGF therapy or in other fields, where systemic VEGF-A levels are of importance for example in evaluating clinical outcome [1820] or in providing risk estimates [46, 47].

It is important to emphasize that for this type of study the number of individual probands is not the determining factor (we had only 12 probands in our study providing the blood samples). It is rather the number of aliquots retrieved from these samples that determines the validity of such a study. For this purpose, we analyzed a total of 476 aliquots that were all processed in an exactly predefined manner, standardizing all pre-analytic steps but the one which was to be investigated. This allowed us to investigate the individual pre-analytical variable's impact on VEGF-A measurements independent from any inter-individual variations in VEGF-A levels.

There are various explanations why certain pre-analytic steps can affect VEGF-A measurements. For example, it can be speculated that individual factors play a certain role as reflected by the parameter “measurement center”. In our study, all centers used the same batch of ELISA kits, so lot variability can be ruled out as an interfering parameter in our study. Beyond the human factor, different types of spectrophotometers for ELISA read-out may play a role. We therefore recommend using one central laboratory experienced in the applied measurement method.

In order to investigate whether the type of assay applied for analysis has an independent effect on VEGF-A level measurements, all samples were analyzed by multiplex bead array in addition to ELISA. We detected significantly lower VEGF-A values using the multiplex bead array technique compared to the ELISA technique. The Bland-Altmann plot in Fig 2.4c, however, displays a horizontal line (except for three outliers). This demonstrates that relative values are comparable, but that the multiplex bead array retrieved consistently lower absolute values at a relatively fixed fraction from ELISA readings in our hands. This phenomenon was described previously for a comparison of ELISA and multiplex bead array for other cytokines, like IL-1β, TNF-α or IFN-γ [48]. The difference in absolute values was detected despite using internal standard curves in both assays. One possible explanation could be that the VEGF-A used for generating the standard curve differs between the two techniques. Indeed, the calibrator protein provided with the VEGF ELISA kit resulted in lower signal levels in both the ELISA and Luminex system compared to the calibrator protein from the Luminex kit (shown in Fig 2.4d and 2.4e). This explains the lower absolute VEGF-A levels measured in the multiplex bead assay. We therefore conclude that both methods can be used for human plasma VEGF-A measurements but that absolute values cannot be compared between the two techniques.

In contrast to “free” recombinant VEGF-A used for generating standard curves, VEGF-A in plasma samples can be bound to proteins and might therefore escape detection. Both assays used in our study measure only free VEGF as confirmed by addition of aflibercept (see S1 Fig).

One very obvious parameter with significant impact on VEGF-A readings is the anticoagulant used for plasma sampling. Since we were interested in measuring free VEGF-A and since it is well established that high levels of VEGF-A are stored in thrombocytes, serum measurements were ruled out for our comparative analysis. However, even between the different plasma anticoagulants, we found significant differences with regard to their potency to reliably suppress thrombocyte activation. As reflected by PF-4 measurements, the highest degree of thrombocyte activation (and therefore the highest risk of plasma being contaminated by VEGF-A released from thrombocytes) was present in the EDTA samples (both in completely filled and half-filled tubes). This is important, since most centers use EDTA as their standard anticoagulant for plasma sampling. However, for reliable measurement of VEGF-A as a biomarker EDTA does not appear to be the ideal plasma anticoagulant. In both PECT and CTAD buffers, considerably less PF-4 was detected which is indicative of less thrombocyte activation. As a consequence, VEGF-A levels measured in PECT and CTAD buffer showed less variability and were significantly lower than values measured from EDTA plasma. These lower VEGF-A levels in PECT and CTAD buffers do more likely reflect the true free plasma VEGF-A levels, while values from EDTA buffers may be higher due to varying degrees of additional VEGF-A released from thrombocytes. In addition, storing of centrifuged samples before plasma separation from the pellet did not affect measurement of VEGF-A when PECT was used as anticoagulant. Similarly, sample storage up to 24 hours before centrifugation did not result in different VEGF-A readings when CTAD or PECT samples were used, while EDTA samples resulted in a wide variability of measured VEGF-A levels when samples were incubated over 24 hours before centrifugation. While PECT buffer is currently not commercially available, CTAD tubes can be obtained as standard clinical equipment. For these reasons and since our experiments of VEGF-spiking into PBS containing EDTA, PECT or CTAD did not show any interference of any of the anticoagulants with the ELISA assay, we recommend the use of CTAD plasma for VEGF-A measurements, which is in accordance with the observations from Zimmermann et al. [49]

Starlinger et al. [50] explored in their study, among other parameters, the influence of a Venflon® versus a Vacutainer® butterfly cannula on the measured VEGF-A levels and did not find an effect on measured VEGF-A levels, but on PF-4 levels. Since our study was in part conducted in preparation for the clinical study CARE-ROP, a study for investigating the efficacy and safety of different ranibizumab dosages for the treatment of retinopathy of prematurity (NCT02134457), we compared neonatal with butterfly cannulas. Similar to the results from Starlinger et al., we did not find a significant effect of these two types of cannulas (butterfly vs. neonatal) on measured VEGF-A levels. Neonatal cannulas can therefore be used for VEGF-A sampling.

Svendsen et al. [40] observed that measured VEGF-A levels are highly dependent on the applied centrifugation force: the higher the centrifugation force, the lower the measured VEGF-A levels, possibly due to better separation of thrombocytes from plasma. In our study, we compared two types of centrifuges (swing-out rotor versus fixed angle rotor) using equivalent settings. Even with identical centrifugal forces, VEGF-A levels differed significantly between the two types of centrifuges, with values from swing-out rotor centrifuges being lower than values from fixed-angle centrifuges. PF-4 values tended also to be lower in the swing-out rotor centrifuge, indicating that less thrombocyte activation occurs and therefore less contamination of free plasma VEGF-A with VEGF-A released from thrombocytes. Consequently, we recommend using the same type of centrifuge with identical settings for all samples acquired during the course of a study, preferentially a swing-out rotor centrifuge.

Intrapersonal VEGF-A levels did not significantly vary over one week. This is in line with Svendsen et al. [40] who also did not find a variation in VEGF-A levels within two weeks, but found variations over longer time periods. The fact that VEGF-A levels from the same person measured twice within one week were highly reproducible in our study, demonstrates not only the reliability of our sampling and measuring method but further emphasizes how strong the confounding effects of the interfering parameters are. The fact that IGF-1 measurements were not affected by the investigated pre-analytic parameters further confirms that these identified parameters are specific confounders for VEGF-A measurements.

In conclusion, our study identified potent confounders of VEGF-A measurements that need to be standardized in order to obtain reliable and reproducible results in clinical studies. Based on our results we recommend the use of CTAD as anticoagulant, a standardized type of centrifuge where possible and one central laboratory for measurements of free VEGF-A from human plasma. Either an ELISA or multiplex bead array method can be used but absolute values are not interchangeable between these two assays.

Supporting Information

S1 Complete Data Set. Excel Sheet containing the dataset underlying the findings in the manuscript.



S1 Fig. ELISA and Luminex standard curves with and without addition of aflibercept.

Both in the ELISA as well in the Luminex method, addition of aflibercept reduced the levels of measured VEGF, thus confirming that both assays measure only free VEGF.




The authors thank Ulrike Hagemann (University of Tuebingen), Susanne Denning (University of Ulm), Marc Leinweber (University of Freiburg), Serap Luick (University of Kiel) and Gerburg Nettels-Hackert (University of Muenster) for their excellent technical assistance.

Author Contributions

Conceived and designed the experiments: HD PH AK TK FZ AS. Performed the experiments: JW HD PH AK TK JCG SMK NS-M FZ AS. Analyzed the data: DB HD PH AK TK NS-M FZ AS. Contributed reagents/materials/analysis tools: DB HD PH AK TK NS-M FZ AS. Wrote the paper: JW DB HD LF PH AK TK NS-M FZ AS.


  1. 1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nature medicine. 2003;9(6):669–76. doi: 10.1038/nm0603-669 pmid:12778165.
  2. 2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature medicine. 1995;1(1):27–31. pmid:7584949.
  3. 3. Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. The New England journal of medicine. 2014;370(8):734–43. doi: 10.1056/NEJMoa1309748 pmid:24552320; PubMed Central PMCID: PMC4010094.
  4. 4. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nature reviews Neuroscience. 2007;8(8):610–22. doi: 10.1038/nrn2175 pmid:17643088.
  5. 5. Alagappan VK, de Boer WI, Misra VK, Mooi WJ, Sharma HS. Angiogenesis and vascular remodeling in chronic airway diseases. Cell biochemistry and biophysics. 2013;67(2):219–34. doi: 10.1007/s12013-013-9713-6 pmid:23975597.
  6. 6. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PTVM. Increased expression of angiogenic growth factors in age-related maculopathy. British Journal of Ophthalmology. 1997;81(2):154–62. doi: 10.1136/bjo.81.2.154. pmid:9059252
  7. 7. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The New England journal of medicine. 2014;370(8):699–708. doi: 10.1056/NEJMoa1308573 pmid:24552317; PubMed Central PMCID: PMC4201043.
  8. 8. Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011;377(9780):1846–54. doi: 10.1016/S0140-6736(11)60545-X pmid:21621716; PubMed Central PMCID: PMC4134127.
  9. 9. Joulain F, Proskorovsky I, Allegra C, Tabernero J, Hoyle M, Iqbal SU, et al. Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. British journal of cancer. 2013;109(7):1735–43. doi: 10.1038/bjc.2013.523 pmid:24045663; PubMed Central PMCID: PMC3790175.
  10. 10. Tabernero J, Van Cutsem E, Lakomý R, Prausová J, Ruff P, van Hazel GA, et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial. European Journal of Cancer. 2014;50(2):320–31. doi: 10.1016/j.ejca.2013.09.013. pmid:24140268
  11. 11. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103–11. doi: 10.1016/S0140-6736(07)61904-7 pmid:18156031.
  12. 12. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. The Lancet. 382(9900):1258–67. doi: 10.1016/S0140-6736(13)61501-9.
  13. 13. Catt Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England journal of medicine. 2011;364(20):1897–908. doi: 10.1056/NEJMoa1102673 pmid:21526923; PubMed Central PMCID: PMC3157322.
  14. 14. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik J-F, Schlingemann RO, Axer-Siegel R, et al. Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study. Ophthalmology. 2011;118(5):831–9. doi: 10.1016/j.ophtha.2010.09.004. pmid:21146229
  15. 15. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–48. doi: 10.1016/j.ophtha.2012.09.006 pmid:23084240.
  16. 16. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010. American journal of ophthalmology. 2012;153(2):209–13 e2. doi: 10.1016/j.ajo.2011.10.016 pmid:22264944.
  17. 17. Skaat A, Chetrit A, Belkin M, Kinori M, Kalter-Leibovici O. Time trends in the incidence and causes of blindness in Israel. American journal of ophthalmology. 2012;153(2):214–21 e1. doi: 10.1016/j.ajo.2011.08.035 pmid:22264945.
  18. 18. Bruhn MA, Townsend AR, Khoon Lee C, Shivasami A, Price TJ, Wrin J, et al. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. International journal of cancer Journal international du cancer. 2014;135(3):731–41. doi: 10.1002/ijc.28698 pmid:24374727.
  19. 19. Pommier AJ, Shaw R, Spencer SK, Morgan SR, Hoff PM, Robertson JD, et al. Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy +/- cediranib. British journal of cancer. 2014;111(8):1590–604. doi: 10.1038/bjc.2014.436 pmid:25121956; PubMed Central PMCID: PMC4200086.
  20. 20. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. Markers of response for the antiangiogenic agent bevacizumab. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013;31(9):1219–30. doi: 10.1200/JCO.2012.46.2762 pmid:23401453.
  21. 21. Lankhorst S, Saleh L, Danser AJ, van den Meiracker AH. Etiology of angiogenesis inhibition-related hypertension. Current opinion in pharmacology. 2014;21C:7–13. doi: 10.1016/j.coph.2014.11.010 pmid:25500206.
  22. 22. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. British journal of cancer. 2007;96(12):1788–95. pmid:17519900
  23. 23. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer. New England Journal of Medicine. 2003;349(5):427–34. doi: 10.1056/NEJMoa021491 pmid:12890841.
  24. 24. Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. The British journal of ophthalmology. 2010;94(9):1215–8. doi: 10.1136/bjo.2008.156810 pmid:20538658.
  25. 25. Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. American journal of ophthalmology. 2012;153(2):327–33 e1. doi: 10.1016/j.ajo.2011.07.005 pmid:21930258.
  26. 26. Klettner A. VEGF-A and its inhibitors in age-related macular degeneration–pharmacokinetic differences and their retinal and systemic implications. J Biochemical and Pharmacological Research. 2014;2(1):8–20.
  27. 27. Ivan Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399–411. doi: 10.1016/j.ophtha.2012.04.015 pmid:22578446.
  28. 28. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. The British journal of ophthalmology. 2014. doi: 10.1136/bjophthalmol-2014-305252 pmid:25001321.
  29. 29. Mittal K, Koon H, Elson P, Triozzi P, Dowlati A, Chen H, et al. Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers. Cancer biology & therapy. 2014;15(8):975–81. doi: 10.4161/cbt.29187 pmid:24842548; PubMed Central PMCID: PMC4119082.
  30. 30. Niers TM, Richel DJ, Meijers JC, Schlingemann RO. Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. PloS one. 2011;6(5):e19873. doi: 10.1371/journal.pone.0019873 pmid:21637343; PubMed Central PMCID: PMC3102663.
  31. 31. Schlingemann RO, Van Noorden CJ, Diekman MJ, Tiller A, Meijers JC, Koolwijk P, et al. VEGF levels in plasma in relation to platelet activation, glycemic control, and microvascular complications in type 1 diabetes. Diabetes care. 2013;36(6):1629–34. doi: 10.2337/dc12-1951 pmid:23321217; PubMed Central PMCID: PMC3661842.
  32. 32. Aguilar-Mahecha A, Kuzyk MA, Domanski D, Borchers CH, Basik M. The effect of pre-analytical variability on the measurement of MRM-MS-based mid- to high-abundance plasma protein biomarkers and a panel of cytokines. PloS one. 2012;7(6):e38290. doi: 10.1371/journal.pone.0038290 pmid:22701622; PubMed Central PMCID: PMC3368926.
  33. 33. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6(4):283–7. doi: 10.1023/ pmid:15166496.
  34. 34. Hoerster R, Muether P, Dahlke C, Mehler K, Oberthur A, Kirchhof B, et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta ophthalmologica. 2013;91(1):e74–5. doi: 10.1111/j.1755-3768.2012.02469.x pmid:22672259.
  35. 35. Carneiro AM, Costa R, Falcao MS, Barthelmes D, Mendonca LS, Fonseca SL, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta ophthalmologica. 2012;90(1):e25–30. doi: 10.1111/j.1755-3768.2011.02240.x pmid:21958440.
  36. 36. Yoshida I, Shiba T, Taniguchi H, Takahashi M, Murano T, Hiruta N, et al. Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2014;252(9):1483–9. doi: 10.1007/s00417-014-2717-0 pmid:25030237.
  37. 37. Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. The British journal of ophthalmology. 2013;97(4):454–9. doi: 10.1136/bjophthalmol-2012-302451 pmid:23385630.
  38. 38. Enders P, Muether PS, Hermann M, Ristau T, Fauser S. Long-Term Alterations of Systemic Vascular Endothelial Growth Factor Levels in Patients Treated with Ranibizumab for Age-Related Macular Degeneration. Retina. 2014. doi: 10.1097/IAE.0000000000000320 pmid:25170863.
  39. 39. Hartmann RC, Auditore JV, Jackson DP. Studies on thrombocytosis. I. Hyperkalemia due to release of potassium from platelets during coagulation. The Journal of clinical investigation. 1958;37(5):699–707. doi: 10.1172/JCI103656 pmid:13539213; PubMed Central PMCID: PMC293142.
  40. 40. Svendsen MN, Brunner N, Christensen IJ, Ytting H, Bentsen C, Lomholt AF, et al. Biological variations in plasma VEGF and VEGFR-1 may compromise their biomarker value in colorectal cancer. Scandinavian journal of clinical and laboratory investigation. 2010;70(7):503–11. doi: 10.3109/00365513.2010.521254 pmid:20873967.
  41. 41. Lee KY, Lee KS, Park SJ, Kim SR, Min KH, Choe YH, et al. Clinical significance of plasma and serum vascular endothelial growth factor in asthma. The Journal of asthma: official journal of the Association for the Care of Asthma. 2008;45(9):735–9. doi: 10.1080/02770900802216775 pmid:18972287.
  42. 42. Ma Y, Zhang Y, Zhao T, Jiang YR. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab. American journal of ophthalmology. 2012;153(2):307–13 e2. doi: 10.1016/j.ajo.2011.08.006 pmid:21982107.
  43. 43. Wang X, Sawada T, Sawada O, Saishin Y, Liu P, Ohji M. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration. American journal of ophthalmology. 2014;158(4):738–44 e1. doi: 10.1016/j.ajo.2014.06.009 pmid:24973606.
  44. 44. Grierson R, Meyer-Rusenberg B, Kunst F, Berna MJ, Richard G, Thill M. Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration. Journal of ocular pharmacology and therapeutics: the official journal of the Association for Ocular Pharmacology and Therapeutics. 2013;29(6):530–8. doi: 10.1089/jop.2012.0013 pmid:23573802.
  45. 45. Wu FP, Hoekman K, Meijer S, Cuesta MA. VEGF and endostatin levels in wound fluid and plasma after breast surgery. Angiogenesis. 2003;6(4):255–7. doi: 10.1023/B:AGEN.0000029410.32264.b0 pmid:15166493.
  46. 46. Kavsak PA, Newman AM, Ko DT, MacRae AR, Jaffe AS. The use of a cytokine panel to define the long-term risk stratification of heart failure/death in patients presenting with chest pain to the emergency department. Clinical Biochemistry. 2010;43(4–5):505–7. doi: 10.1016/j.clinbiochem.2009.11.004. pmid:19913003
  47. 47. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. The New England journal of medicine. 2004;350(7):672–83. doi: 10.1056/NEJMoa031884 pmid:14764923.
  48. 48. dupont NC, Wang K, Wadhwa PD, Culhane JF, Nelson EL. Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. Journal of reproductive immunology. 2005;66(2):175–91. doi: 10.1016/j.jri.2005.03.005 pmid:16029895.
  49. 49. Zimmermann R, Koenig J, Zingsem J, Weisbach V, Strasser E, Ringwald J, et al. Effect of specimen anticoagulation on the measurement of circulating platelet-derived growth factors. Clinical chemistry. 2005;51(12):2365–8. doi: 10.1373/clinchem.2005.055558 pmid:16306098.
  50. 50. Starlinger P, Alidzanovic L, Schauer D, Brugger P, Sommerfeldt S, Kuehrer I, et al. Platelet-stored angiogenesis factors: clinical monitoring is prone to artifacts. Disease markers. 2011;31(2):55–65. doi: 10.3233/DMA-2011-0798 pmid:21896999; PubMed Central PMCID: PMC3826483.